(Q53933241)

22 May 2018

title

Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. (English)

1 reference

22 May 2018

1 reference

1 reference

Zanetti G

1

1 reference

22 May 2018

Harbarth SJ

2

1 reference

22 May 2018

Trampuz A

3

1 reference

22 May 2018

Ganeo M

4

1 reference

22 May 2018

Mosimann F

5

1 reference

22 May 2018

Chautemps R

6

1 reference

22 May 2018

Morel P

7

1 reference

22 May 2018

Lew D

8

1 reference

22 May 2018

Zimmerli W

9

1 reference

22 May 2018

Lange J

10

1 reference

22 May 2018

Glauser M

11

1 reference

22 May 2018

publication date

1 February 1999

1 reference

22 May 2018

International Journal of Antimicrobial Agents

published in

1 reference

22 May 2018

volume

11

1 reference

22 May 2018

issue

2

1 reference

22 May 2018

page(s)

107-113

1 reference

22 May 2018

Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Meropenem: a microbiological overview

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Imipenem (N-F-thienamycin) versus netilmicin plus clindamycin. A controlled and randomized comparison in intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

A prospective randomized trial of imipenem-cilastatin versus clindamycin/tobramycin in the treatment of intra-abdominal and pelvic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections. German and Austrian Imipenem/Cilastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

Imipenem/cilastatin as monotherapy in severe infections: comparison with cefotaxime in combination with metronidazole and cloxacillin. Report from a Norwegian Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900104-6

7 January 2021

10.1016/S0924-8579(98)00104-6

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018